In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: Results of the CANWARD 2007-2009 study

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 3, 2011, Pages 348-355

  Walkty, Andrew ^a,b   Adam, Heather J ^a,b   Laverdière, Michel ^c   Karlowsky, James A ^a,b   Hoban, Daryl J ^a,b   Zhanel, George G ^b  

^a Diagnostic Services of Manitoba Inc   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Ceftobiprole; Hospitals; Vancomycin

Indexed keywords

CEFAZOLIN; CEFEPIME; CEFTOBIPROLE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; CANADA; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79951940148     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.032     Document Type: Article

References (34)

1. Bogdanovich T., Ednie L.M., Shapiro S., Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 2005, 49:4210-4219.
2. Boucher H.W., Corey G.R. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46:S344-S349.
3. Chahine E.B. Ceftobiprole: farewell or just a delay?. Am J Health-Syst Pharm 2010, 67:981.
4. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed. M7-A7 2006, CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing, 20th informational supplement. M100-S20 2010, CLSI, Wayne, PA.
6. Craig W.A., Andes D.R. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 2008, 52:3492-3496.
7. Dauner D.G., Nelson R.E., Taketa D.C. Ceftobiprole: a novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am. J. Health-Syst. Pharm. 2010, 67:983-993.
8. Davies T.A., Page M.G.P., Shang W., Andrew T., Kania M., Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2007, 51:2621-2624.
9. Deshpande L., Rhomberg P.R., Fritsche T.R., Sader H.S., Jones R.N. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 2004, 50:73-75.
10. Fritsche T.R., Sader H.S., Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results of the SENTRY antimicrobial surveillance program (2005-2006). Diagn. Microbiol. Infect. Dis. 2008, 61:86-95.
11. Health Canada Zeftera (ceftobiprole medocaril) for injection-discontinuation of sale-notice to hospitals http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/zeftera_nth-aah-eng.php.
12. Hoban D.J., Zhanel G.G. Introduction to the CANWARD study, 2007-2009. Diagn. Microbiol. Infect. Dis. 2011, 69:289-290.
13. Janssen-Ortho Inc Zeftera product monograph 2008, Toronto, Ontario, Canada.
14. Jones R.N., Deshpande L.M., Mutnick A.H., Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 2002, 50:915-932.
15. Kim S.H., Kim K.H., Kim H.B., Kim N.J., Kim E.C., Oh M.D., Choe K.W. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2008, 52:192-197.
16. Kimko H., Xu X., Nandy P., Samtani M.N., Strauss R.S., Bagchi P., Noel G.J. Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 2009, 53:3371-3374.
17. Kosowska K., Hoellman D.B., Lin G., Clark C., Credito K., McGhee P., Dewasse B., Bozdogan B., Shapiro S., Appelbaum P.C. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 2005, 49:1932-1942.
18. Lodise T.P., McKinnon P.S., Levine D.P., Rybak M.J. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 2007, 51:3731-3733.
19. Lodise T.P., Pypstra R., Kahn J.B., Murthy B.P., Kimko H.C., Bush K., Noel G.J., Drusano G.L. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 2007, 51:2378-2387.
20. Naber C.K. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin. Infect. Dis. 2009, 48:S231-S237.
21. Noel G.J., Bush K., Bagchi P., Ianus J., Strauss R.S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 2008, 46:647-655.
22. Noel G.J., Strauss R.S., Amsler K., Heep M., Pypstra R., Solomkin J.S. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother. 2008, 52:37-44.
23. Noel G.J., Strauss R.S., Shah A., Bagchi P. Ceftobiprole (BPR) versus ceftazidime (CAZ) combined with linezolid (LZD) for treatment of patients with nosocomial pneumonia (NP) 2008.
24. Oliveira D.C., de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2002, 46:2155-2161.
25. Queenan A.M., Shang W., Kania M., Page M.G.P., Bush K. Interaction of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 2007, 51:3089-3095.
26. Rubinstein E., Kollef M.H., Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46:S378-S385.
27. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., Dalovisio J.R., Levine D.P. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health-Syst. Pharm. 2009, 66:82-98.
28. Simner P.J., Zhanel G.G., Pitout J., Tailor F., McCracken M., Mulvey M.R., Lagacé-Wiens P.R.S., Adam H.J., Hoban D.J. Prevalence and characterization of extended-spectrum β-lactamase- and ampC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 2011, 69:326-334. the Canadian Antimicrobial Resistance Alliance,.
29. Stryjewski M.E., Chambers H.F. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46:S368-S377.
30. Stryjewski M.E., Szczech L.A., Benjamin D.K., Inrig J.K., Kanafani Z.A., Engemann J.J., Chu V.H., Joyce M.J., Reller L.B., Corey G.R., Fowler V.G. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2007, 44:190-196.
31. Zhanel G.G., Adam H.J., Low D.E., Blondeau J., DeCorby M., Karlowsky J., Weshnoweski B., Vashisht R., Wierzbowski A., Hoban D.J. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 2011, 69:291-306. the Canadian Antimicrobial Resistance Alliance.
32. Zhanel G.G., DeCorby M., Nichol K.A., Baudry P.J., Karlowsky J.A., Lagace-Wiens P.R., McCracken M., Mulvey M.R., Hoban D.J. Characterization of methicillin-resistant Staphylococcus aureus vancomycin-resistant enterococci and extended spectrum beta-lactamase producing Escherichia coli in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005/2006. Can. J. Infect. Dis. Med. Microbiol. 2008, 19:243-249.
33. Zhanel G.G., Lam A., Schweizer F., Thomson K., Walkty A., Rubinstein E., Gin A.S., Hoban D.J., Noreddin A.M., Karlowsky J.A. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am. J. Clin. Dermatol. 2008, 9:245-254.
34. Zhanel G.G., Karlowsky J.A., DeCorby M., Nichol K.A., Wierzbowski A., Baudry P.J., Lagace-Wiens P., Walkty A., Schweizer F., Adam H., McCracken M., Mulvey M.R., Hoban D.J. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2007). Can. J. Infect. Dis. Med. Microbiol. 2009, 20:9A-19A. the Canadian Antimicrobial Resistance Alliance.